What are Mesenchymal Stem Cells?
Mesenchymal stem cells (MSCs) are a prototypical adult stem cell with capacity for self-renewal and differentiation with a broad tissue distribution. Initially described in bone marrow, MSCs have the capacity to differentiate into mesoderm- and nonmesoderm-derived tissues. The endogenous role for MSCs is maintenance of stem cell niches (classically the hematopoietic), and as such, MSCs participate in organ homeostasis, wound healing, and successful aging. From a therapeutic perspective, and facilitated by the ease of preparation and immunologic privilege, MSCs are emerging as an extremely promising therapeutic agent for tissue regeneration. Studies in animal models of myocardial infarction have demonstrated the ability of transplanted MSCs to engraft and differentiate into cardiomyocytes and vasculature cells, recruit endogenous cardiac stem cells, and secrete a wide array of paracrine factors.
Together, these properties can be harnessed to both prevent and reverse remodeling in the ischemically injured ventricle. In proof-of-concept and phase I clinical trials, MSC therapy improved left ventricular function, induced reverse remodeling, and decreased scar size.
The above is a "careful" assessment by Joshua Hare- cardiologist, but despite thousands of studies "the medical establishment" is not yet totally convinced. The image you see, is what has been proven to happen upon injury by the godfather of MSCs- Arnold Caplan-i.e. activation of MSC precursers or pericytes from the outer walls of arteries to "come to the rescue" after injury and at the same time building a wall around the area to prevent run-a-way inflammation and attacks by own T-cells.
MSCs are because of the above fact (lined at the outer walls of arteries) so relevant to Fat Cells- since adipose tissue is a highly vascularized tissue, hence contains so many MSC precursers.
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news
Dove Medical PressBone marrow mesenchymal stem cells as nuclear donors improve viability and health of cloned horses
Dove Medical Press
Of the total deliveries, 95.2% (20/21) of the MSC-foals were viable, compared to 52.9% (9/17) of the AF-foals (p<0.05). In addition, the AF-foals had more physiological abnormalities at birth than the MSC-foals; 90.5% (19/21) of the MSC-delivered foals ...
Alzheimer's News TodayTexas A&M and Celltex Partnering on a Stem Cell-related Alzheimer's Treatment
Alzheimer's News Today
The fluid-filled sacs, which scientists call vesicles, transport material inside a cell. But cells often release them, and when this happens, they are called exosomes. Researchers at Texas A&M and Celltex plans a multiyear study on whether inflammation ...
Endpoints NewsStem cell co Mesoblast reports PhIII trial success in children with GVHD
The company, called Mesoblast $MESO, was testing its allogeneic mesenchymal stem cell product called remestemcel-L. The off-the-shelf therapy is meant to treat Graft Versus Host Disease, a condition that often arises in blood cancer patients who've had ...
and more »
UQ NewsTwo in one: human placenta stem cells hold a dual benefit
“In the past, each of these stem cell would have been harvested and spun together and then given to the patient,” Dr Shafiee said. “Now it is just a dual cell, which means the cell has two specific functions at the same time.” The new stem cells are ...
Seacoastonline.comStem cell therapy proving effective as arthritis treatment
PORTSMOUTH - Stem cell therapy is beginning to change the way arthritis and other chronic pain conditions are being treated. Mesenchymal stem cell therapy activates the body's own self-healing mechanisms for cellular and tissue regeneration and repair ...
Stem Cell Therapy And Aplastic Anemia
Checkbiotech.org (press release)
Asia-Pacific Mesenchymal Stem Cells Market 2017 – Lonza, Thermo Fisher, Bio-Techne, ATCC
Global Cell Therapy Systems Market to Witness Soaring Growth During 2017-2027
Find Market Research By Abhishek Budholiya (press release) (blog) all 58 news articles »
American VeterinarianStem Cell Therapy in Veterinary Medicine
In one of the largest studies of stem cell therapy, 113 race-horses with an injury to the superficial digital flexor tendon demonstrated a reinjury rate of 27% after bone marrow–derived mesenchymal stem cell therapy, which was statistically ...
United States Mesenchymal Stem Cells Market Snapshot 2018-2022|(Key Players, Types, Applications and Regions)
The Important Events 24
Mesenchymal Stem Cells Market Growth Opportunities By Regions, Type & Application; Trend Forecast To 2022
satPRnews (press release)
Stem cell vaccine immunizes lab mice against multiple cancers
EurekAlert National Cancer Institute- FierceBiotech all 95 news articles »
Brunswick NewsStem-cell therapy used to restore joint health
Advanced Regenerative Healthcare uses mesenchymal stem cells, which are more viable and effective for a longer period of time after being injected into the affected area of the patient's body. Essentially, the stem cells stimulate the body's own tissue ...
How Safe Is Stem Cell Therapy?
Checkbiotech.org (press release)
Dr. Joel Singer Announces Study of Stem Cell Treatments for Knee Osteoarthritis
Outlook of Global Mesenchymal Stem Cells Market: Research Report during 2018-2022
satPRnews (press release) Facts of Week all 26 news articles »
Mesenchymal Stem Cells Market Research Growth by Manufacturers, Regions, Type and Application, Forecast...
Global Mesenchymal Stem Cells Market provides detailed analysis of Market Overview, Market Drivers & restraints, Trends and Opportunities, Potential Application, competitive landscape and business tactics for decision making. Mesenchymal Stem Cells ...
Primary Endpoint Successfully Achieved in Mesoblast's Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease
GlobeNewswire (press release)
NEW YORK and MELBOURNE, Australia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Phase 3 trial of its allogeneic mesenchymal stem cell product candidate MSC-100-IV (remestemcel-L) in children with ...
and more »